TABLE 3.

Development of resistance to APV in WT and M184V clade B isolates^a

APV concn (μM)	Wk	4246-WT	4246-M184V	3350-WT	3350-M184V
0	1	WT	WT (M184V)	WT (L63P, V77I, I93L)	WT (L63P, V77I, I93L; M184V)
0.1	23	V32I, I54I/Mb	WT	WT	WT
0.4	30	V32I, I54M	WT	V32I, M46I, I54Lb	WT
0.4	34-35	V32I, I54M	V32I/V, N37S	V32I, M46I, I54L	M46I/L
10	46-47	V32I, M46I, I54M	V32I, M46I/M	V32I, M46I, I54L	M46L
10	52	V32I, M46I, I54M	V32I/V, M46I, I54I/Vb	ND	M46I, I54I/Lb
10	55	NDc	ND	ND	M46I, I54Lb
10	58	V32I, M46I, I54M	V32I/V, M46I, I54V	ND	ND

^aGenotypic analysis was performed at designated weeks based on RT activity to determine the time to appearance of resistance mutations. The baseline genotype included mutations shown in parentheses that were sustained at subsequent time points.

^bTime to first appearance of the major resistance mutations, I54M/V/L, that confer high-level phenotypic resistance to protease inhibitors.

^cND, not done.